World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 88 13021 12256 182 175 555 33698

Rolf A. Stahel publications per year

The chart shows the history of publications by Rolf A. Stahel between 1979 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Rolf A. Stahel published across 47 years, from 1979 to 2025, averaging 13.4 papers a year. Output peaked at 55 publications in 2023. 31 of the 631 publications appeared in the last two years.

No. of publications
10 20 30 40 50
Bar chart. Horizontal axis: year, 1979 to 2025. Vertical axis: number of publications, 0 to 55. Peak 55 publications in 2023. 1979: 1 publication 1980: 0 publications 1981: 0 publications 1982: 3 publications 1983: 1 publication 1984: 1 publication 1985: 6 publications 1986: 2 publications 1987: 2 publications 1988: 8 publications 1989: 7 publications 1990: 6 publications 1991: 13 publications 1992: 12 publications 1993: 6 publications 1994: 18 publications 1995: 8 publications 1996: 5 publications 1997: 12 publications 1998: 5 publications 1999: 6 publications 2000: 10 publications 2001: 11 publications 2002: 7 publications 2003: 24 publications 2004: 17 publications 2005: 22 publications 2006: 17 publications 2007: 17 publications 2008: 13 publications 2009: 15 publications 2010: 17 publications 2011: 21 publications 2012: 28 publications 2013: 19 publications 2014: 29 publications 2015: 31 publications 2016: 13 publications 2017: 29 publications 2018: 15 publications 2019: 24 publications 2020: 15 publications 2021: 16 publications 2022: 13 publications 2023: 55 publications 2024: 25 publications 2025: 6 publications
1979 2025

631 publications in total across all disciplines

View publications per year as a table
Rolf A. Stahel: publications per year, 1979 to 2025
Year Publications
1979 1
1980 0
1981 0
1982 3
1983 1
1984 1
1985 6
1986 2
1987 2
1988 8
1989 7
1990 6
1991 13
1992 12
1993 6
1994 18
1995 8
1996 5
1997 12
1998 5
1999 6
2000 10
2001 11
2002 7
2003 24
2004 17
2005 22
2006 17
2007 17
2008 13
2009 15
2010 17
2011 21
2012 28
2013 19
2014 29
2015 31
2016 13
2017 29
2018 15
2019 24
2020 15
2021 16
2022 13
2023 55
2024 25
2025 6
Total 631
Download as CSV

Rolf A. Stahel publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Rolf A. Stahel sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 541–560 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 555 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537 555
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Rolf A. Stahel D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Rolf A. Stahel sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 88–89 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970 88
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Rolf A. Stahel is affiliated with the University of Zurich in Switzerland and has a research profile primarily focused on medicine, with a significant emphasis on pulmonary and respiratory medicine and oncology. Their publication record spans several subfields, including cancer research, radiology, nuclear medicine, and even economics and econometrics.

The scientist's work is centered around key topics such as lung cancer treatments and mutations, occupational and environmental lung diseases, lung cancer diagnosis and treatment, cancer immunotherapy and biomarkers, lung cancer research studies, pleural and pulmonary diseases, and cancer genomics and diagnostics.

Recent publications by Rolf A. Stahel reflect ongoing contributions to oncology and respiratory medicine through clinical trial reports and guideline papers. Notable papers include:

  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, 2022, The Lancet Oncology
  • EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours, 2021, Annals of Oncology
  • A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial, 2020, Annals of Oncology
  • ESMO Guidance for Reporting Oncology real-World evidence (GROW), 2023, Annals of Oncology
  • Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14), 2020, Journal of Thoracic Oncology

They frequently collaborate with other researchers, notably Solange Peters, Urania Dafni, Heidi Roschitzki-Voser, Barbara Ruepp, and Roswitha Kammler. These collaborations have contributed to a substantial body of work within the domains of lung cancer and oncology.

Rolf A. Stahel's research is frequently published in specialized venues, indicating a focused engagement with the academic community in thoracic oncology and respiratory medicine. The most common publication venues include:

  • Lung Cancer
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Journal of Clinical Oncology
  • Cancer Treatment Reviews

The scientist's body of work encompasses a broad spectrum of lung and cancer-related medical research, underscoring an emphasis on clinical trials, treatment protocols, and diagnostic guidelines within respiratory medicine and oncology.

Best Publications

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell

  • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

    Ken A. Olaussen;Ariane Dunant;Pierre Fouret;Elisabeth Brambilla

  • CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

    Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg

  • Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

    A Scherpereel;P Astoul;P Baas;T Berghmans

  • Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

    Daniel C. Betticher;Shu Fang Hsu Schmitz;Martin Tötsch;Eva Hansen

  • 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    J. Vansteenkiste;L. Crinò;C. Dooms;J. Y. Douillard

  • Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

    Viviana Galimberti;Bernard F Cole;Giuseppe Viale;Giuseppe Viale;Paolo Veronesi;Paolo Veronesi

  • CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells

    Silke Aigner;Zev M. Sthoeger;Mina Fogel;Erich Weber

  • 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    W.E.E. Eberhardt;D. De Ruysscher;W. Weder;C. Le Péchoux

  • Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P. Baas;D. Fennell;K. M. Kerr;P. E. Van Schil

  • Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

    T Le Chevalier;G Scagliotti;R Natale;S Danson

  • Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

    Sherene Loi;Anita Giobbie-Hurder;Andrea Gombos;Thomas Bachelot

  • Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

    W Weder;R A Stahel;J Bernhard;S Bodis

  • Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

    Miklos Pless;Roger Stupp;Roger Stupp;Hans Beat Ris;Rolf A. Stahel

  • Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop

    Robert Pirker;Felix J F Herth;Keith M. Kerr;Martin Filipits

  • CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

    J Lundin;Anders Osterborg;G Brittinger;Derek Crowther

  • Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

    Keith M. Kerr;Lukas Bubendorf;Martin J. Edelman;Antonio Marchetti

  • High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment.

    J Willuda;A Honegger;R Waibel;P A Schubiger

  • Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

    Oliver Gautschi;Colette Bigosch;Barbara Huegli;Monika Jermann

  • Staging and prognostic factors in small cell lung cancer: a consensus report

    Rolf Arno R. Stahel;Robert Ginsberg;Klaus Havemann;Fred R Hirsch

Frequent Co-Authors

Walter Weder
Walter Weder University of Zurich
Solange Peters
Solange Peters University Hospital of Lausanne
Lukas Bubendorf
Lukas Bubendorf University Hospital of Basel
Uwe Zangemeister-Wittke
Uwe Zangemeister-Wittke University of Bern
Keith M. Kerr
Keith M. Kerr Aberdeen Royal Infirmary
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Roger Stupp
Roger Stupp Northwestern University
Rafael Rosell
Rafael Rosell Autonomous University of Barcelona
Fiona H Blackhall
Fiona H Blackhall University of Manchester
Paul Baas
Paul Baas Antoni van Leeuwenhoek Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing medicine in the USA opens the door to diverse online degrees and accelerated career pathways, especially in nursing and healthcare leadership. If you’re ready to advance your clinical expertise, a 1 year dnp program online offers a fast-track approach to earning your Doctor of Nursing Practice. For those seeking less intensive options, the easiest online dnp programs may provide a balanced track while still delivering high-quality education.

Students interested in entering the workforce sooner might consider fast track lpn programs, which prepare you for practical nursing quickly and efficiently. Specializations are also in demand; for example, aspiring psychiatric nurse practitioners can explore fast track mental health nursing programs to make a difference in mental health care settings.

Whether you’re aiming for hands-on patient care or leadership roles, these online pathways offer the flexibility and speed to help you achieve your goals in the dynamic field of medicine.

Best Scientists Citing Rolf A. Stahel

Trending Scientists

Recently Published Articles